These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12502353)

  • 1. First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling.
    Daines RA; Pendrak I; Sham K; Van Aller GS; Konstantinidis AK; Lonsdale JT; Janson CA; Qiu X; Brandt M; Khandekar SS; Silverman C; Head MS
    J Med Chem; 2003 Jan; 46(1):5-8. PubMed ID: 12502353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III (FabH) as potential antibacterial agents.
    Shi L; Fang RQ; Zhu ZW; Yang Y; Cheng K; Zhong WQ; Zhu HL
    Eur J Med Chem; 2010 Sep; 45(9):4358-64. PubMed ID: 20557983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors.
    Lv PC; Wang KR; Yang Y; Mao WJ; Chen J; Xiong J; Zhu HL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6750-4. PubMed ID: 19836235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, substrate specificity, and inhibition of the Streptococcus pneumoniae beta-ketoacyl-acyl carrier protein synthase III (FabH).
    Khandekar SS; Gentry DR; Van Aller GS; Warren P; Xiang H; Silverman C; Doyle ML; Chambers PA; Konstantinidis AK; Brandt M; Daines RA; Lonsdale JT
    J Biol Chem; 2001 Aug; 276(32):30024-30. PubMed ID: 11375394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and structure-activity relationships of pyrazole derivatives as potential FabH inhibitors.
    Lv PC; Sun J; Luo Y; Yang Y; Zhu HL
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4657-60. PubMed ID: 20594840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of vinylogous carbamates as a novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Li HQ; Luo Y; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(15):4454-9. PubMed ID: 21742506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of C(7) modified chrysin derivatives designing to inhibit beta-ketoacyl-acyl carrier protein synthase III (FabH) as antibiotics.
    Li HQ; Shi L; Li QS; Liu PG; Luo Y; Zhao J; Zhu HL
    Bioorg Med Chem; 2009 Sep; 17(17):6264-9. PubMed ID: 19664929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkyl-CoA disulfides as inhibitors and mechanistic probes for FabH enzymes.
    Alhamadsheh MM; Musayev F; Komissarov AA; Sachdeva S; Wright HT; Scarsdale N; Florova G; Reynolds KA
    Chem Biol; 2007 May; 14(5):513-24. PubMed ID: 17524982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and dynamical aspects of Streptococcus gordonii FabH through molecular docking and MD simulations.
    Shamim A; Abbasi SW; Azam SS
    J Mol Graph Model; 2015 Jul; 60():180-96. PubMed ID: 26059477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of a substrate complex of Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A.
    Musayev F; Sachdeva S; Scarsdale JN; Reynolds KA; Wright HT
    J Mol Biol; 2005 Mar; 346(5):1313-21. PubMed ID: 15713483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of platensimycin analogs.
    Shen HC; Ding FX; Singh SB; Parthasarathy G; Soisson SM; Ha SN; Chen X; Kodali S; Wang J; Dorso K; Tata JR; Hammond ML; Maccoss M; Colletti SL
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1623-7. PubMed ID: 19233644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of bacterial FabH suggest a molecular basis for the substrate specificity of the enzyme.
    Gajiwala KS; Margosiak S; Lu J; Cortez J; Su Y; Nie Z; Appelt K
    FEBS Lett; 2009 Sep; 583(17):2939-46. PubMed ID: 19665020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure and substrate specificity of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus.
    Qiu X; Choudhry AE; Janson CA; Grooms M; Daines RA; Lonsdale JT; Khandekar SS
    Protein Sci; 2005 Aug; 14(8):2087-94. PubMed ID: 15987898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PqsBC, a Condensing Enzyme in the Biosynthesis of the Pseudomonas aeruginosa Quinolone Signal: CRYSTAL STRUCTURE, INHIBITION, AND REACTION MECHANISM.
    Drees SL; Li C; Prasetya F; Saleem M; Dreveny I; Williams P; Hennecke U; Emsley J; Fetzner S
    J Biol Chem; 2016 Mar; 291(13):6610-24. PubMed ID: 26811339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents.
    Nie Z; Perretta C; Lu J; Su Y; Margosiak S; Gajiwala KS; Cortez J; Nikulin V; Yager KM; Appelt K; Chu S
    J Med Chem; 2005 Mar; 48(5):1596-609. PubMed ID: 15743201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping.
    McKinney DC; Eyermann CJ; Gu RF; Hu J; Kazmirski SL; Lahiri SD; McKenzie AR; Shapiro AB; Breault G
    ACS Infect Dis; 2016 Jul; 2(7):456-64. PubMed ID: 27626097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of urea derivatives from o-hydroxybenzylamines and phenylisocyanate as potential FabH inhibitors.
    Li ZL; Li QS; Zhang HJ; Hu Y; Zhu DD; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(15):4413-20. PubMed ID: 21752655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combined approach of docking and 3D QSAR study of beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Ashek A; Cho SJ
    Bioorg Med Chem; 2006 Mar; 14(5):1474-82. PubMed ID: 16275103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a scintillation proximity assay for beta-ketoacyl-acyl carrier protein synthase III.
    He X; Mueller JP; Reynolds KA
    Anal Biochem; 2000 Jun; 282(1):107-14. PubMed ID: 10860506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.